Contributions
Abstract: PB1724
Type: Publication Only
Session title: Myeloproliferative neoplasms - Clinical
Background
Myeloproliferative neoplasms (MPNs) are heterogenous myeloid malignancies that include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). There are few Latin American studies focused on these diseases.
Aims
In this work, we describe the clinical characteristics and frequency of the JAK2 V617F mutation, as well as the treatment patterns and survival of patients with the most frequent Philadelphia MPN neoplasms treated in a referral hospital in Mexico City.
Methods
A retrospective analysis of the medical history of patients with Ph negative myeloproliferative neoplasms treated at the National Cancer Institute of Mexico City was carried out to describe the variables considered for inclusion.
Results
Among the patients with essential thrombocythemia, 53% were men and 47% women, with a mean age of 51 years, 67% underwent bone marrow biopsy, the JAK2 V671F mutation was detected in 47%, the mean platelet count at diagnosis was 1 016 x109/L (±SD 68 x109/L), 80% received treatment cytoreductive with hydroxyurea.
50% of the patients with polycythemia vera were women, the mean age at diagnosis was 63 years, 100% had a bone marrow biopsy, the JAK2 V617F mutation was found in 75%, the mean hemoglobin level at diagnosis was 18.6 g/dL (± SD 2.6 g/dL), 100% received treatment with hydroxyurea plus a low dose of aspirin.
Most of the patients with myelofibrosis were women (67%) and had a mean age at diagnosis of 68 years, a bone marrow biopsy was performed in 100% and the JAK2 V617F mutation was found in 67%, the mean hemoglobin level at diagnosis was 10.7 g / dL (± SD 4 g / dL), mean platelet count at diagnosis was 333 x109 / L (± SD 275 x109 / l), only 33% received treatment with JAK2 inhibitors.
Conclusion
Myeloproliferative neoplasms are rare in our environment, however, they present a behavior similar to that reported in other parts of the world. Efforts should be made to identify molecular alterations in our patients that could imply an improvement in access to novel treatments. Although our study has many limitations, it is expected to serve as the basis for the creation of a national registry that will help improve the study of patients with myeloproliferative neoplasms.
Keyword(s): Essential Thrombocytemia, Myelofibrosis, Polycythemia vera
Abstract: PB1724
Type: Publication Only
Session title: Myeloproliferative neoplasms - Clinical
Background
Myeloproliferative neoplasms (MPNs) are heterogenous myeloid malignancies that include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). There are few Latin American studies focused on these diseases.
Aims
In this work, we describe the clinical characteristics and frequency of the JAK2 V617F mutation, as well as the treatment patterns and survival of patients with the most frequent Philadelphia MPN neoplasms treated in a referral hospital in Mexico City.
Methods
A retrospective analysis of the medical history of patients with Ph negative myeloproliferative neoplasms treated at the National Cancer Institute of Mexico City was carried out to describe the variables considered for inclusion.
Results
Among the patients with essential thrombocythemia, 53% were men and 47% women, with a mean age of 51 years, 67% underwent bone marrow biopsy, the JAK2 V671F mutation was detected in 47%, the mean platelet count at diagnosis was 1 016 x109/L (±SD 68 x109/L), 80% received treatment cytoreductive with hydroxyurea.
50% of the patients with polycythemia vera were women, the mean age at diagnosis was 63 years, 100% had a bone marrow biopsy, the JAK2 V617F mutation was found in 75%, the mean hemoglobin level at diagnosis was 18.6 g/dL (± SD 2.6 g/dL), 100% received treatment with hydroxyurea plus a low dose of aspirin.
Most of the patients with myelofibrosis were women (67%) and had a mean age at diagnosis of 68 years, a bone marrow biopsy was performed in 100% and the JAK2 V617F mutation was found in 67%, the mean hemoglobin level at diagnosis was 10.7 g / dL (± SD 4 g / dL), mean platelet count at diagnosis was 333 x109 / L (± SD 275 x109 / l), only 33% received treatment with JAK2 inhibitors.
Conclusion
Myeloproliferative neoplasms are rare in our environment, however, they present a behavior similar to that reported in other parts of the world. Efforts should be made to identify molecular alterations in our patients that could imply an improvement in access to novel treatments. Although our study has many limitations, it is expected to serve as the basis for the creation of a national registry that will help improve the study of patients with myeloproliferative neoplasms.
Keyword(s): Essential Thrombocytemia, Myelofibrosis, Polycythemia vera